Sionna Therapeutics (SION) director Orbimed Advisors sold 510,583 shares for $22.9M at an average $44.94 under a 10b5-1 plan
Insider transactions reported
Orbimed Advisors Llc (director at Sionna Therapeutics Inc., SION) reported that they sold 510,583 shares for $22.9M at an average $44.94 between Apr 14, 2026 and Apr 16, 2026. After these transactions the filing shows 3,020,119 shares held indirectly (See footnotes).
- Reporting person
- Orbimed Advisors Llc
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Apr 14, 2026 | Open-market sale (S) | Common Stock1, 2, 3 | -47,814 | $44.51 | $2.13M | 3,482,888 indirect |
| Apr 15, 2026 | Open-market sale (S) | Common Stock1, 2, 3 | -235,863 | $44.64 | $10.5M | 3,247,025 indirect |
| Apr 16, 2026 | Open-market sale (S) | Common Stock1, 2, 3 | -226,906 | $45.34 | $10.3M | 3,020,119 indirect |
Holdings before and after
- Common Stock: 3,530,702 to 3,020,119 indirect, See footnotes
Footnotes from the filing
- 1. These securities were sold pursuant to a 10b5-1 plan.
- 2. These securities are held of record by OrbiMed Private Investments VIII, LP ( OPI VIII ). OrbiMed Capital GP VIII LLC ( GP VIII ) is the general partner of OPI VIII and OrbiMed Advisors LLC ( OrbiMed Advisors ) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
- 3. This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act ), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
FAQ
What did Orbimed Advisors report in this SION Form 4?
Orbimed Advisors Llc (director at Sionna Therapeutics Inc., SION) reported that they sold 510,583 shares for $22.9M at an average $44.94 between Apr 14, 2026 and Apr 16, 2026. After these transactions the filing shows 3,020,119 shares held indirectly (See footnotes).
How many SION shares does Orbimed Advisors hold after this filing?
The filing shows 3,020,119 shares held indirectly (See footnotes) after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this SION insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for SION
Across the 13 sessions after earlier SION headlines, the stock closed higher 5 times and lower 8 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SION | SPY |
|---|---|---|---|
| Apr 7, 2026 | Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium | -1.7% | +0.0% |
| Mar 2, 2026 | Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results | -7.2% | +0.1% |
| Feb 24, 2026 | Citizens initiated coverage on Sionna Therapeutics with a new price target | +3.4% | +0.7% |
| Feb 23, 2026 | Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences | +1.7% | -1.0% |
| Feb 4, 2026 | Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 | -7.1% | -0.5% |
| Jan 5, 2026 | Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | +4.2% | +0.7% |
Earlier insider filings at SION
- Mar 6, 2026Chief Legal Officer Fitzpatrick Jennifer exercised 10,250 shares at a strike of $6.11 and sold $347,019 worth of shares (10,250 units at $33.86) (SEC Form 4)
- Feb 5, 2026Director Thompson Peter A. sold $1,379,866 worth of shares (30,953 units at $44.58) (SEC Form 4)
- Feb 5, 2026Director Orbimed Advisors Llc sold $1,379,866 worth of shares (30,953 units at $44.58) (SEC Form 4)
- Jan 26, 2026Large owner Tpg Gp A, Llc sold $10,000,000 worth of shares (250,000 units at $40.00) (SEC Form 4)
- Jan 6, 2026SEC Form 4 filed by Chief Medical Officer Mckee Charlotte
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2025
Follow SION and get a push notification the moment its next story breaks.